Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for OPHLY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for OPHLY and 80,000+ other tickers.
See exactly how OPHLY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for OPHLY and 80,000+ other tickers.
Ono Pharmaceutical Co., Ltd., along with its subsidiaries, operates globally, engaging in the research, development, procurement, and commercialization of pharmaceutical products and diagnostic reagents. Its current portfolio features a range of established treatments, notably in oncology, with products such as the intravenous infusions OPDIVO and KYPROLIS, alongside MEKTOVI, VELEXBRU, ADLUMIZ (tablets), and BRAFTOVI (capsules) for various malignant tumors. Other specialized oncology support includes EMEND capsules and PROEMEND intravenous injections to manage chemotherapy-induced nausea and…
OSAKA, Japan--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced the results of the phase 2 clinical study (ONO-4578-08 study) of the EP4 antagonist ONO-4578 in patients with previously untreated, HER2-negative unresectable advanced or recurrent gastric cancer (including gastroesophageal junction cancer).
OSAKA, Japan & MONTREAL--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that it has entered into an agreement to expand the drug discovery collaboration agreement with Congruence Therapeutics (Headquarters: Montreal, Quebec, Canada; CEO: Clarissa Desjardins; “Congruence”) for the discovery of novel small molecule modulators against multiple protein targets in the areas of neurology and immunology. In December 2024, we entere.
OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) under the accelerated approval pathway for tirabrutinib, a highly selective irreversible, second generation Bruton tyrosine kinase inhibitor, for the treatment of relapsed or refractory primar.
Ono Pharmaceutical Co., Ltd. (OPHLY) Presents at 44th Annual J.P.
Ono Pharmaceutical Co., Ltd. (OTCPK:OPHLF) Q1 FY2025 Earnings Conference Call August 1, 2025 1:00 AM ET Company Participants Hirokazu Kitada - Corporate Participant Sales and Marketing - Corporate Participant Hiroyuki Takahashi - Director of Oncology Business Division, Sales and Marketing Masaki Ito - Corporate Executive Officer & Div.